Influence of contact system deficiencies during cardiopulmonary bypass

Thrombosis and Haemostasis

Volumn 85, Issue 2, 2001, Pages 191-192

  Agostini, A ^a   Cugno, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; APROTININ; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; CALPAIN; COMPLEMENT COMPONENT C1S INHIBITOR; HEPARIN; HIGH MOLECULAR WEIGHT KININOGEN; INFUSORIAL EARTH; KALLIKREIN; KALLIKREIN INHIBITOR; KAOLIN; LYSINE DERIVATIVE; PROTHROMBIN; THROMBIN;

BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG MONITORING; FIBRINOLYSIS; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0035122457     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615673     Document Type: Note

References (20)

1. Cardiopulmonary bypass: Coagulation and inflammation issues. Introduction
2. Biologic activities of the contact factors in vivo. Potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis
3. Activation of the classical pathway of complement by Hageman factor fragment
4. The tissue factor pathway: How it has become a "prima ballerina"
5. Formation of Cqs-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha2-plasmin-inhibitor complexes during cardiopulmonary bypass
6. Aprotinin inhibits the contact, neuthrophil and platelet activation systems during simulated extracorporeal perfusion
7. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
8. Tissue factor is expressed on monocytes during simulated extracorporeal circulation
9. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass
10. High molecular weight kininogen deficiency: A patient who underwent cardiac surgery
11. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass
12. Bleeding complications associated with cardiopulmonary bypass
13. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant
14. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex
15. Cardiopulmonary bypass increases plasma bradykinin concentrations
16. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins
17. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery
18. Aprotinin: A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery
19. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints
20. Aprotinin and tranexamic acid for high transfusion risk cardiac surgery